Incyte CorporationNasdaq: INCY
Health Care · Biotechnology
$98.30
-0.70%
Vol: 1.3M
Research Digest
Friday, June 19, 2026
Incyte agrees to acquire Vega Therapeutics for up to $2B and gains FDA Priority Review for zilurgisertib in FOP.
Incyte announced on June 8, 2026 a definitive agreement to acquire Vega Therapeutics (a subsidiary of Star Therapeutics) for $1.25 billion upfront plus up to $750 million in sales-based milestones ($2 billion total), bringing VGA039 — a first-in-class Phase 3 monoclonal antibody targeting von Willebrand disease — into the pipeline with Breakthrough Therapy and orphan drug designations. Separately, the FDA accepted the NDA for zilurgisertib (in fibrodysplasia ossificans progressiva) under Priority Review with a PDUFA date of September 26, 2026, after positive pivotal Phase 2 data from the Mirum partnership. At the EHA 2026 congress, Incyte also presented updated Phase 1 data for INCA033989 in myelofibrosis and Phase 3 frontMIND results for tafasitamab showing significantly prolonged progression-free survival in high-risk DLBCL. The Vega deal is expected to generate an R&D charge of ~$1.25 billion upon close (Q3 2026), representing the principal near-term financial risk.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15Incyte presented positive Phase 3 frontMIND DLBCL data and new INCA033989 myelofibrosis/ET responses at EHA 2026 on June 13, supporting key pipeline catalysts.Positive▶
On June 13, 2026, Incyte presented pivotal Phase 3 frontMIND trial data at the European Hematology Association (EHA) 2026 Congress, showing tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP cut the risk of progression or death by roughly 25% versus standard of care in first-line high-risk diffuse large B-cell lymphoma (DLBCL/HGBL). The same day, Incyte reported new positive data showing its first-in-class mutCALR-targeted antibody INCA033989 produced rapid, robust and sustained clinical and molecular responses in myelofibrosis and essential thrombocythemia patients. These readouts strengthen Incyte's hematology/oncology pipeline beyond its core Jakafi franchise and follow a busy stretch that included the June 8 agreement to acquire Vega Therapeutics for $1.25B (up to $2.0B with milestones). The data matters because it could expand the addressable market for tafasitamab into a large first-line DLBCL setting and validate a novel mechanism in myeloproliferative neoplasms. The bear case is that these are conference datasets rather than approvals, frontMIND still requires regulatory filing and review, and INCA033989 remains early stage with execution and competitive risk in crowded oncology markets.
Jun 14Incyte shares jumped about 3.8% after several analysts raised price targets following its $1.25B acquisition of Vega Therapeutics, plus positive late-stage pipeline data.Positive▶
Incyte agreed to acquire Vega Therapeutics (a wholly owned subsidiary of Star Therapeutics) for $1.25 billion, prompting shares to climb roughly 3.8% as several firms raised price targets on the deal. The acquisition adds to a strengthening pipeline that includes positive topline Phase 3 frontMIND data for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP in first-line DLBCL, positive INCA033989 results, and an FDA Breakthrough Therapy designation for essential thrombocythemia with Type 1 CALR mutations. The stock trades near $107, close to its 52-week high of $110.57, up about 5.5% YTD. The deal matters because it expands Incyte beyond its Jakafi/Opzelura-dependent revenue base (recent quarterly revenue $1.22B, +17.3% y/y). The bear case: a $1.25B outlay carries integration and clinical execution risk, and Incyte remains heavily reliant on Jakafi as key patents and competition loom.
May 21Incyte expands Genesis AI drug discovery deal worth up to $1B, plus Edison strategic collaborationPositive▶
On May 20, Incyte and Genesis Molecular AI expanded their drug-discovery collaboration: Genesis received $120M upfront with milestones potentially exceeding $1B if five initial targets are met, with Genesis training its GEMS platform on Incyte data. On May 19, Incyte and Edison Scientific announced a separate strategic deal to deploy the Kosmos AI platform for R&D. The new CFO Suketu Upadhyay started May 4. Q1 revenue rose 21% YoY to $1.27B. More than 20 abstracts will be presented at EHA 2026 and Phase 3 frontMIND tafasitamab data will be presented at ASCO on May 30. BofA maintained Buy with $124 PT, HC Wainwright kept $135 target. Risk: ruxolitinib LOE looms and these AI deals may take years to translate into pipeline assets.
May 20Incyte highlights Phase 3 tafasitamab data at ASCO 2026; Q1 revenue +20% YoY and BofA maintains Buy with $124 PT.Positive▶
Incyte will highlight new Phase 3 tafasitamab data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Q1 2026 revenue was $1.27B (up 20% YoY) with non-GAAP EPS of $1.81, both ahead of Wall Street expectations, driven by Jakafi, Monjuvi, Niktimvo, and Opzelura. The late-stage pipeline now includes 10 Phase 3 studies. INCY trades at $95.60 on May 19, with BofA maintaining Buy at $124 PT and a mean price target of $110.50 (16.4% upside). Suketu (Suky) Upadhyay was named EVP and CFO effective May 4. Australia's TGA approved NIKTIMVO (axatilimab) for chronic GvHD, the first marketing authorization outside the US.
May 19Incyte presents at RBC 2026 Global Healthcare Conference on May 19 amid ongoing Q1 momentum and recent CFO transition.Positive▶
Incyte is scheduled to present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026 at 10:30 am EDT, giving management an opportunity to update investors on the post-FDA-approval rollout of Jakafi XR (approved May 1) and the recent KRAS G12D Phase 3 DAWN-303 launch announced May 7. The presentation follows a strong Q1 2026 with revenue up 21% YoY to $1.27B and the May 4 appointment of Suketu Upadhyay as new CFO. HC Wainwright reiterated Buy with a $135 price target on May 4. Investors will be watching for additional commentary on Opzelura growth, EHA congress data, and full Phase 3 frontMIND results due at ASCO on May 30. Risk lies in pipeline execution and the impending CFO transition. Sentiment is constructive but the move is incremental rather than a fresh catalyst.
May 18Incyte presented 24-week Phase 3 TRuE-AD4 data on Opzelura with 84.3% EASI75 response; BofA reiterated Buy on May 14.Positive▶
Incyte announced 24-week long-term data from the Phase 3 TRuE-AD4 trial of Opzelura cream in adults with moderate atopic dermatitis on May 7, with 84.3% EASI75 response at Week 24, presented at the 2026 EADV Symposium. The FDA approved Jakafi XR Extended-Release Tablets on May 1 for Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease. Suketu Upadhyay was named EVP and CFO effective May 4, 2026. Incyte announced more than 20 abstracts accepted for the EHA 2026 Congress on May 12. Bank of America maintained Buy on May 14 and HC Wainwright reiterated Buy with a $135 PT on May 4, while Wells Fargo kept a Hold rating on May 13.
May 15Incyte named Suky Upadhyay CFO effective May 4 and unveiled 20+ EHA 2026 abstracts as Q1 revenue grew 21% to $1.27B with FDA approval of Jakari XRPositive▶
Incyte (INCY) named Suketu (Suky) Upadhyay Executive Vice President and CFO effective May 4, 2026, taking over global finance, capital allocation, investor relations, ESG, IT and facilities. Q1 2026 total revenue grew 21% to $1.27B with total net sales up 20% to $1.10B and non-GAAP EPS of $1.81, both ahead of consensus. On May 1, 2026 FDA approved Jakari XR. On May 12, 2026 the company announced more than 20 abstracts accepted for presentation at the European Hematology Association (EHA) 2026 Congress, with full Phase 3 frontMIND data of tafasitamab in first-line DLBCL slated for ASCO 2026 on May 30. On May 7 the company reported 24-week long-term data from Phase 3 TRuE-AD4 of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis with good tolerability and only 1.7% application site reactions, supporting a Type-II variation in the EU. A new Phase 3 DAWN-303 trial targeting KRAS G12D pancreatic cancer started on May 8. HC Wainwright reiterated Buy with a $135 PT and BofA Securities maintained Buy. Stock traded $97.12-$99.36 on May 15, 2026.
May 14Incyte names Suketu Upadhyay as CFO effective May 4; Q1 revenue up 21% to $1.27B with strong Jakafi/Opzelura growthPositive▶
Incyte appointed Suketu (Suky) Upadhyay as Executive VP and CFO effective May 4, 2026, leading global finance, capital allocation and IR. Q1 2026 total revenue reached $1.27B (+21% YoY) with Jakafi at $758M (+7%) and Opzelura at $143M (+20%). Company will present 20+ abstracts at EHA Congress June 11-14 including Phase 3 tafasitamab DLBCL data. New Phase 3 DAWN-303 trial targeting KRAS G12D pancreatic cancer launched with orphan designation. Recent FDA approval of Jakafi XR (extended-release ruxolitinib). Investor conferences at BofA May 13 and RBC May 19. Risk: Jakafi LOE timeline and pipeline execution remain key.
May 13Incyte named Suky Upadhyay as CFO effective May 4 and is targeting KRAS G12D pancreatic cancer with a new Phase 3 trial (DAWN-303), with Phase 3 DLBCL data due at ASCO May 30.Positive▶
Incyte appointed Suketu Suky Upadhyay as EVP and CFO effective May 4, granting inducement options on 38,429 shares plus RSUs. The company is initiating a Phase 3 DAWN-303 trial targeting KRAS G12D pancreatic cancer. Final 24-week Phase 3 TRuE-AD4 data for Opzelura cream were presented at EADV (84.3% EASI75 at Week 24). Full Phase 3 frontMIND data for tafasitamab in first-line DLBCL will be presented at ASCO on May 30. Q1 2026 revenue was $1.27B (+21% YoY) with EPS of $1.47 vs. $1.07 estimate. Stock at $99.13 on May 12.
May 12Incyte FDA-approved Jakafi XR extended-release on May 1 and posted strong 24-week Phase 3 TRuE-AD4 Opzelura data (84.3% EASI75) on May 7-9.Positive▶
Incyte received FDA approval on May 1, 2026 for Jakafi XR (once-daily extended-release ruxolitinib) for myelofibrosis, polycythemia vera and graft-versus-host disease, lifecycle-extending its top drug. On May 7-9, 24-week data from the Phase 3 TRuE-AD4 study showed Opzelura achieved 84.3% EASI75 at Week 24 in atopic dermatitis, presented at EADV in Athens. On May 8, Incyte announced a new Phase 3 DAWN-303 trial in KRAS G12D pancreatic cancer with orphan designation. Q1 2026 results beat estimates with revenue $1.27B (+21% YoY) and EPS $1.47 vs $1.07 est. New CFO Suky Upadhyay received inducement equity grants with a May 4 start. HC Wainwright reiterated Buy with $135 PT.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| INCYINCYTE | $98.30 | -0.70% | +1.2% | 10.7x | 0.79 | $19.6B |
| ABBVABBVIE | $216.79 | -2.01% | +2.0% | 13.3x | 0.31 | $382.5B |
| AMGNAMGEN | $337.43 | -1.24% | +1.8% | 14.4x | 0.42 | $182.2B |
| GILDGILEAD | $123.76 | -1.35% | -5.3% | 12.8x | 0.33 | $153.7B |
| VRTXVERTEX | $451.94 | -1.54% | +4.9% | 21.0x | 0.31 | $114.6B |
| REGNREGENERON | $609.97 | +0.34% | -6.1% | 11.3x | 0.24 | $63.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.